Processa Pharmaceuticals, Inc PCSA 深 滬
已收盤 08-22 16:00:00 美东时间
0.218
+0.011
+5.31%
華盛通- 最 高0.225
- 今 開0.207
- 成交量 642.90万股
- 最 低 0.202
- 昨 收 0.207
- 總市值 1097.61万
- 52周最高 1.50
- 市盈率 靜 --
- 換手率 12.77%
- 52周最低 0.15
- 委 比 89.00%
- 總股本 5034.91万
- 歷史最高 284.80
- 量 比 3.07
- 振 幅 11.11%
- 歷史最低 0.15
- 每 手 1
- 風險率 3.38%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Processa Pharma Q2 EPS $(0.25) Misses $(0.20) Estimate
Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.20) by 25 percent. This is a 75.25 percent increase over losses of $(1.01) per share from
08-08 05:54
Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies
Processa Pharmaceuticals secured strategic investments and is exploring blockchain-based assets as part of its financial strategy to diversify capital, enhance flexibility, and reduce dilution for shareholders. The company aims to leverage emerging financial technologies for long-term value creation while maintaining regulatory compliance. CEO George Ng highlighted the focus on innovative financial strategies to support shareholders and stakehold...
08-07 12:30
Processa Pharmaceuticals Reschedules Annual Shareholder Meeting
Processa Pharmaceuticals ( ($PCSA) ) has provided an announcement. On June 30, ...
07-16 00:57
Processa Pharmaceuticals Provides Portfolio and Business Update
Processa Pharmaceuticals announced updates on their product pipeline, including a signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852, with potential milestone payments of up to $454 million. The company continues enrolling patients in the Phase 2 study of PCS6422 for metastatic breast cancer, expecting interim data in the second half of 2025. Processa also strengthened its balance sheet with a $7M capit...
07-01 13:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
HC Wainwright & Co. Maintains Buy on Processa Pharmaceuticals, Lowers Price Target to $2
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers the price target from $6 to $2.
06-30 18:57
Processa Pharmaceuticals Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
06-30 18:56
快讯 | Processa Pharmaceuticals, Inc. : H.c. Wainwright 将目标价从6美元下调至2美元
Processa Pharmaceuticals, Inc. : H.c. Wainwright Cuts Target Price to $2 From $6
06-30 18:08
Processa Pharmaceuticals Announces Licensing Deal with Intact
Processa Pharmaceuticals ( ($PCSA) ) has issued an update. On June 17, 2025, Pr...
06-17 22:57
Processa Pharmaceuticals (PCSA) Shares Soar 150% On Gastroparesis Drug Deal
Processa Pharmaceuticals' stock is surging after licensing a gastroparesis drug to Intact Therapeutics. The deal promises milestone payments and royalties for Processa.
06-17 22:17
